GlassScriptPhysician profile
Vinita Jain
NPI 1659426922
$7,503.70
in general payments reported to CMS, 2019-2025
39 companies · $848 in 2025
The $848 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $953 · 2021: $1,547 · 2022: $1,059 · 2023: $1,078 · 2024: $1,026 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,952.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,815.04 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $796.14 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $738.87 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $640.79 | 2019-2024 | Trelegy Ellipta |
| Pfizer INC. | $613.79 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $562.92 | 2019-2024 | Xifaxan |
| Novo Nordisk INC | $238.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $207.09 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.48 | 2023-2025 | |
| Astellas Pharma US INC | $163.45 | 2020-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $126.78 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $104.82 | 2019-2021 | |
| Abbvie INC. | $103.63 | 2021-2022 | |
| Amgen INC. | $99.56 | 2019-2025 | Otezla, Repatha, Repatha |
| Biohaven Pharmaceuticals, INC. | $90.88 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $87.34 | 2024-2025 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $85.25 | 2021-2024 | Nuzyra |
| Theratechnologies INC. | $80.76 | 2024-2025 | Trogarzo, Egrifta |
| Novartis Pharmaceuticals Corporation | $76.55 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $73.13 | 2024-2025 | Voquezna |
| Acorda Therapeutics, INC | $73.08 | 2022-2023 | Inbrija, Ampyra |
| Therapeuticsmd, INC. | $72.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $56.75 | 2019-2023 | Verquvo, Januvia, Belsomra |
| Edwards Lifesciences Corporation | $46.61 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Dermira, INC. | $44.84 | 2020 | |
| Xeris Pharmaceuticals, INC. | $38.77 | 2023 | Gvoke Hypopen |
| Oxford Immunotec USA INC | $30.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.86 | 2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $25.44 | 2022 | |
| Sumitomo Pharma America, INC. | $23.54 | 2024 | Gemtesa |
| Abbott Laboratories | $22.70 | 2022 | |
| Amarin Pharma, INC. | $22.44 | 2019 | |
| Cequr Corporation | $21.04 | 2023 | Cequr Simplicity |
| Idorsia Pharmaceuticals US INC | $20.52 | 2023 | Quviviq |
| Biogen, INC. | $19.39 | 2021 | |
| Alfasigma USA, INC. | $19.29 | 2022 | |
| Esperion Therapeutics, INC. | $17.40 | 2024 | Nexletol |
| Nestle Healthcare Nutrition INC. | $15.29 | 2023 | |
| Janssen Biotech, INC. | $14.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinita Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.